Overview

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

Status:
Recruiting
Trial end date:
2025-01-21
Target enrollment:
Participant gender:
Summary
This study is a prospective single-arm phase II clinical study. Advanced non-small cell lung cancer patients with FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University